Management of Acute Exacerbation of Cough‑Variant Asthma Secondary to Influenza Pneumonia

Antiviral Therapy for Influenza

Initiate oral oseltamivir 75 mg every 12 h for 5 days in patients who present within 48 h of symptom onset and have fever > 38 °C with acute influenza‑like illness. [Evidence: strong] [1][2]3
In hospitalized patients with severe illness, antiviral therapy may still be beneficial when started after 48 h, although the supporting data are limited. [Evidence: limited] [1][4]
Reduce the oseltamivir dose by 50 % (75 mg once daily) for patients with creatinine clearance < 30 mL/min. [Evidence: strong] [2][3]
Immunocompromised or very elderly patients may receive antiviral treatment even in the absence of documented fever. [Evidence: moderate] [1][5]
Early initiation of antiviral therapy (within 48 h) is associated with reduced antibiotic utilization and lower hospitalization rates. [Evidence: moderate] 6

First‑line oral therapy should be co‑amoxiclav or a tetracycline. [Evidence: strong] [2][3]7
For patients intolerant of penicillins, a macrolide (clarithromycin or erythromycin) or a fluoroquinolone active against Streptococcus pneumoniae and Staphylococcus aureus is an acceptable alternative. [Evidence: moderate] [2][3]
Antibiotics should be administered within 4 hours of hospital admission. [Evidence: strong] [2][3]7
A typical course duration is 7 days for uncomplicated, non‑severe pneumonia. [Evidence: strong] [1][3]

Begin immediate intravenous combination therapy with a broad‑spectrum β‑lactamase‑stable agent (co‑amoxiclav or a second/third‑generation cephalosporin such as cefuroxime or cefotaxime) plus a macrolide (clarithromycin or erythromycin). [Evidence: strong] [3][8]4
This regimen provides double coverage for the most likely bacterial pathogens (S. pneumoniae and S. aureus) and also targets atypical organisms including Legionella spp. [Evidence: strong] [8][9]
An alternative is a fluoroquinolone with enhanced pneumococcal activity (e.g., levofloxacin) combined with a broad‑spectrum β‑lactam or a macrolide. [Evidence: moderate] [3][8]9
Add MRSA‑active agents (e.g., vancomycin or linezolid) when the patient has recent hospitalization or fails to improve on empirical therapy. [Evidence: moderate] [8][9]
Treat severe, microbiologically undefined pneumonia for 10 days; extend to 14–21 days if S. aureus or Gram‑negative enteric bacilli are suspected or confirmed. [Evidence: strong] [3][8]
Switch from intravenous to oral antibiotics once clinical improvement is evident and the patient has been afebrile for 24 hours. [Evidence: strong] [3][8]9

Deliver repetitive short‑acting β₂‑agonist (SABA) doses every 20 minutes during the first hour of treatment. [Evidence: strong] 10
Provide supplemental oxygen to maintain target oxygen saturation in moderate to severe exacerbations. [Evidence: strong] 10
Administer oral systemic corticosteroids early in the course of the exacerbation. [Evidence: strong] 10
Do not double the dose of inhaled corticosteroids during an exacerbation, as this strategy is ineffective. [Evidence: strong] 10

Use objective lung‑function measurements (spirometry or peak expiratory flow) to assess exacerbation severity, rather than relying solely on symptoms. [Evidence: strong] 10
Arrange a follow‑up clinical review for patients who experienced significant complications or worsening of their underlying disease. [Evidence: moderate] 1
Avoid routine antibiotic prescription for influenza without radiographic pneumonia; otherwise well adults with acute bronchitis do not require antibiotics. [Evidence: strong] [2][3]7
Patients with cough‑variant asthma are at higher risk for complications; consider antibiotics when lower‑respiratory features are present. [Evidence: moderate] [2][3]
Initiate empiric therapy promptly based on clinical presentation; do not delay treatment while awaiting definitive diagnostic confirmation. [Evidence: strong] 11